Development of a rapid neutralization assay for the detection of neutralizing antibodies against coxsackievirus B1.

• A rapid Elispot-based neutralization assay against Coxsackievirus B1 (CVB1) was successfully developed. • The CVB1 Nt-Elispot is objective, highly sensitive, efficient, and high-throughput. • The CVB1 Nt-Elispot could be applied in the screening of anti-CVB1 neutralizing monoclonal antibodies. • The CVB1 Nt-Elispot could be used to detect NAb levels against CVB1 in large cohorts. Coxsackievirus B1 (CVB1) is a major pathogen that causes viral myocarditis and aseptic meningitis and is implicated as a cause of type 1 diabetes mellitus. The rapid detection of neutralizing antibodies can help in the prevention and diagnosis of viral infection. The traditional cytopathic effect (CPE)-based neutralization assay (Nt-CPE) is time-consuming and labor-intensive. In this study, an efficient neutralization test based on an enzyme-linked immunospot assay and a monoclonal antibody 2E6 against CVB1 (Nt-Elispot) was developed. In this optimal Nt-Elispot, a multiplicity of infection (MOI) of 1 per well was set as the infection dose, and an incubation time of 18 hours was selected as the checkpoint. Compared with Nt-CPE, Nt-Elispot significantly shortened the detection period and displayed a good correlation with it. This established CVB1 Nt-Elispot could be applied to efficiently screen neutralizing antibodies and evaluate the level of NAb against CVB1 in large cohorts. [ABSTRACT FROM AUTHOR]